Celldex Therapeutics, Inc. (CLDX)
- Previous Close
41.21 - Open
41.18 - Bid 41.04 x 200
- Ask 41.21 x 100
- Day's Range
41.01 - 41.88 - 52 Week Range
22.11 - 53.18 - Volume
381,409 - Avg. Volume
938,160 - Market Cap (intraday)
2.716B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-2.86 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70.29
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
www.celldex.comRecent News: CLDX
Performance Overview: CLDX
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLDX
Valuation Measures
Market Cap
2.72B
Enterprise Value
1.89B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
348.60
Price/Book (mrq)
3.24
Enterprise Value/Revenue
312.00
Enterprise Value/EBITDA
-12.88
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.73%
Return on Equity (ttm)
-25.39%
Revenue (ttm)
6.07M
Net Income Avi to Common (ttm)
-144.88M
Diluted EPS (ttm)
-2.86
Balance Sheet and Cash Flow
Total Cash (mrq)
823.85M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-54.98M
Research Analysis: CLDX
Company Insights: CLDX
CLDX does not have Company Insights